However, an integrated molecular analysis of 358 baseline tumors from HCC patients enrolled in the GO30140 Phase 1b and IMbrave 150 Phase III trials and treated with atezo + bev, with atezolizumab alone, or with sorafenib has shown that PD-L1 expression did not significantly correlate with improved clinical outcomes following the atezo + bev combination therapy, yet a high PD-L1 mRNA expression and Teff gene signature, as well as a high density of CD8+ T cells and enriched inflammatory response pathways remain associated with the benefit of the atezo + bev combination therapy [227]. Here, CD8A is linked to hepatocellular carcinoma.